B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins

Blood

Volumn 123, Issue 10, 2014, Pages 1512-1515

  Ng, Patrick P ^a   Kuo, Chiung Chi ^a   Wang, Stanley ^a   Einav, Shirit ^a   Arcaini, Luca ^b   Paulli, Marco ^b   Portlock, Carol S ^c   Marcotrigiano, Joseph ^d   Tarr, Alexander ^e   Ball, Jonathan ^e   Levy, Ronald ^a   Levy, Shoshana ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIGEN; VIRUS PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; CELL EXPANSION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOREACTIVITY; LABORATORY TEST; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MARGINAL ZONE LYMPHOMA; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; TREATMENT RESPONSE; VIRION;

ANIMALS; CELL LINE; GENES, IMMUNOGLOBULIN; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOMA, B-CELL; RECEPTORS, ANTIGEN, B-CELL; VIRAL PROTEINS;

EID: 84897541727     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-532895     Document Type: Article

References (20)

1. Gu H, Kitamura D, Rajewsky K. B cell development regulated by gene rearrangement: arrest of maturation by membrane-bound D mu protein and selection of DH element reading frames. Cell. 1991;65(1):47-54. (Pubitemid 121001212)
2. Kitamura D, Roes J, Kühn R, Rajewsky KA. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature. 1991;350(6317):423-426. (Pubitemid 21912244)
3. Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006;176(10):5715-5719.
4. Chan CH, Hadlock KG, Foung SK, Levy S. V (H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood. 2001;97(4):1023-1026. (Pubitemid 32154288)
5. Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood. 2008;111(3):1344-1356. (Pubitemid 351213421)
6. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89-94. (Pubitemid 34753478)
7. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood. 2001;98(13):3745-3749.
8. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59(1):169-177.
9. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445. (Pubitemid 24030569)
10. Ng PP, Jia M, Patel KG, et al. A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proc Natl Acad Sci USA. 2012;109(36):14526-14531.
11. Whidby J, Mateu G, Scarborough H, Demeler B, Grakoui A, Marcotrigiano J. Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J Virol. 2009;83(21):11078-11089.
12. Tarr AW, Urbanowicz RA, Hamed MR, et al. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype. J Virol. 2011;85(9):4246-4257.
13. Sautto G, Mancini N, Clementi M, Burioni R. Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII). Viruses. 2012;4(11):2924-2944.
14. Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol. 2013;369:113-142.
15. Gorny MK, Pan R, Williams C, et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology. 2012;427(2):198-207.
16. Ohshima N, Iba Y, Kubota-Koketsu R, Asano Y, Okuno Y, Kurosawa Y. Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J Virol. 2011;85(21):11048-11057.
17. Lingwood D, McTamney PM, Yassine HM, et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature. 2012;489(7417):566-570.
18. Moriishi K, Matsuura Y. Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol. 2012;3:54.
19. Neveu G, Barouch-Bentov R, Ziv-Av A, Gerber D, Jacob Y, Einav S. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathog. 2012;8(8):e1002845.
20. Murray CL, Jones CT, Tassello J, Rice CM. Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus. J Virol. 2007;81(19):10220-10231. (Pubitemid 47463297)